{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T05:41:36Z","timestamp":1792734096567,"version":"4.5.0"},"reference-count":47,"publisher":"Oxford University Press (OUP)","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"am","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"European Organisation for Research and Treatment","award":["013-2021"],"award-info":[{"award-number":["013-2021"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>It is unclear whether glioma subtypes differ in health-related quality of life (HRQoL) over time.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We analyzed data from the CODAGLIO 2.0 database, comprising 16 randomized controlled trials with HRQoL assessed using the EORTC QLQ-C30 and QLQ-BN20 questionnaires. Differences in mean HRQoL at baseline (before postoperative treatments) and 3 months were compared across glioma subtypes. Linear mixed models (LMMs) were used to identify factors independently associated with HRQoL, and anchor-based minimally important differences determined clinical relevance.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>A total of 4,301 patients had baseline HRQoL data; 75% completed follow-up. In stratified analyses, at 3 months, physical, social, role, and cognitive functioning were statistically and clinically significantly worse in glioblastoma than in astrocytoma or oligodendroglioma. In adjusted LMMs, compared with glioblastoma, patients with astrocytoma had worse physical (\u22122.78, 95% CI, \u22124.68 to \u22121.01) and cognitive functioning (\u22123.63, \u22126.18 to \u22121.05), more pain (2.74, 0.41-4.95), communication deficits (5.03, 2.44-7.66), and seizures (4.49, 2.55-6.72). Patients with oligodendroglioma had worse social functioning (\u22125.39, \u221210.57 to \u22120.11), communication deficits (7.40, 1.63-12.81), and seizures (8.61, 4.17-14.26). None of these differences exceeded clinical relevance thresholds. Performance status was the only variable associated with clinically meaningful HRQoL changes across most scales.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>At 3 months, patients with glioblastoma show clinically worse HRQoL than IDH-mutant glioma patients in unadjusted analyses. However, after adjusting for clinical variables, glioblastoma patients exhibit statistically but not clinically better HRQoL in several domains. Performance status emerges as the key factor independently associated with HRQoL and should play a central role in clinical decision-making.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/neuonc\/noag231","type":"journal-article","created":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T11:46:34Z","timestamp":1790682394000},"source":"Crossref","is-referenced-by-count":0,"title":["Health-related quality of life in glioma subtypes: A pooled analysis of 16 randomized trials from the CODAGLIO 2.0 project"],"prefix":"10.1093","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6300-332X","authenticated-orcid":false,"given":"Ogechukwu A","family":"Asogwa","sequence":"first","affiliation":[{"name":"Department of Neurology, Leiden University Medical Center , Leiden,","place":["The Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linda","family":"Dirven","sequence":"additional","affiliation":[{"name":"Department of Neurology, Leiden University Medical Center , Leiden,","place":["The Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5710-5127","authenticated-orcid":false,"given":"Martin J","family":"van den Bent","sequence":"additional","affiliation":[{"name":"The Brain Tumor Center at Erasmus MC Cancer Institute, Erasmus Medical Center , Rotterdam,","place":["The Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2574-4850","authenticated-orcid":false,"given":"Neil K","family":"Aaronson","sequence":"additional","affiliation":[{"name":"Division of Psychosocial Research and Epidemiology, The Netherlands Cancer Institute , Amsterdam,","place":["The Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8871-4654","authenticated-orcid":false,"given":"Brigitta G","family":"Baumert","sequence":"additional","affiliation":[{"name":"Institute of Radiation-Oncology, Cantonal Hospital Graub\u00fcnden , Chur,","place":["Switzerland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alba A","family":"Brandes","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, AUSL-IRCCS Scienze Neurologiche , Bologna,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul M","family":"Clement","sequence":"additional","affiliation":[{"name":"Department of Oncology, KU Leuven , Leuven,","place":["Belgium"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Corneel","family":"Coens","sequence":"additional","affiliation":[{"name":"Quality of Life Department, European Organisation for Research and Treatment of Cancer , Brussels,","place":["Belgium"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-9159-2761","authenticated-orcid":false,"given":"Thierry","family":"Gorlia","sequence":"additional","affiliation":[{"name":"Quality of Life Department, European Organisation for Research and Treatment of Cancer , Brussels,","place":["Belgium"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ulrich","family":"Herrlinger","sequence":"additional","affiliation":[{"name":"Department of Neurooncology, Center for Neurology and Center for Integrated Oncology, University of Bonn Medical Center , Bonn,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6181-2895","authenticated-orcid":false,"given":"Caroline","family":"Hertler","sequence":"additional","affiliation":[{"name":"Department of Neurology, University Hospital and University of Zurich , Zurich,","place":["Switzerland"]},{"name":"Palliative Care Center, Department of Radiation Oncology (ii), University Hospital and University of Zurich , Zurich,","place":["Switzerland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florence","family":"Keime-Guibert","sequence":"additional","affiliation":[{"name":"Institut de Recherche International Servier , Gif sur Yvette,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9408-3278","authenticated-orcid":false,"given":"Emilie","family":"Le Rhun","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, Clinical Neuroscience Center, University Hospital and University of Zurich , Zurich,","place":["Switzerland"]},{"name":"Department of Medical Oncology and Hematology, University Hospital and University of Zurich , Zurich,","place":["Switzerland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-2243-7921","authenticated-orcid":false,"given":"Luigi","family":"Lim","sequence":"additional","affiliation":[{"name":"Quality of Life Department, European Organisation for Research and Treatment of Cancer , Brussels,","place":["Belgium"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8410-4939","authenticated-orcid":false,"given":"Annika","family":"Malmstr\u00f6m","sequence":"additional","affiliation":[{"name":"Clinical Department of Geriatrics and Palliative Medicine in Link\u00f6ping, Region \u00d6sterg\u00f6tland , Link\u00f6ping,","place":["Sweden"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0631-672X","authenticated-orcid":false,"given":"Christine","family":"Marosi","sequence":"additional","affiliation":[{"name":"Department of Medicine I, Division of Oncology, Medical University of Vienna , Vienna,","place":["Austria"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Martinelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2251-9933","authenticated-orcid":false,"given":"Matthijs","family":"van der Meulen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8317-2881","authenticated-orcid":false,"given":"Kathy","family":"Oliver","sequence":"additional","affiliation":[{"name":"International Brain Tumour Alliance , Tadworth, Surrey,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9407-6916","authenticated-orcid":false,"given":"Andrea","family":"Pace","sequence":"additional","affiliation":[{"name":"IRCCS Regina Elena Cancer Institute, Neuro-Oncology Unit , Rome,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia","family":"Panciroli","sequence":"additional","affiliation":[{"name":"Clinical Investigation Unit\u2014Institut Catal\u00e0 d\u2019Oncologia , Badalona,","place":["Spain"]},{"name":"Neurology Unit\u2014I.R.C.C.S. Ospedale San Raffaele , Milan,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2257-3147","authenticated-orcid":false,"given":"Jaap C","family":"Reijneveld","sequence":"additional","affiliation":[{"name":"Department of Neurology and Brain Tumour Center Amsterdam, Amsterdam University Medical Center , Amsterdam,","place":["The Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2824-3720","authenticated-orcid":false,"given":"Mirjam","family":"Renovanz","sequence":"additional","affiliation":[{"name":"Department of Neurology and Interdisciplinary Neuro-Oncology, Hertie Institute for Clinical Brain Research, Eberhard Karls University , T\u00fcbingen,","place":["Germany"]},{"name":"Center for Neuro-Oncology, Comprehensive Cancer Center T\u00fcbingen-Stuttgart, University Hospital T\u00fcbingen , T\u00fcbingen,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3897-214X","authenticated-orcid":false,"given":"Patrick","family":"Roth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8178-5089","authenticated-orcid":false,"given":"Clemens","family":"Seidel","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, University of Leipzig Medical Center , Leipzig,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5483-3118","authenticated-orcid":false,"given":"Roger","family":"Stupp","sequence":"additional","affiliation":[{"name":"Department of Oncology, Centre Hospitalier Universitaire Vaudois (CHUV), University of Lausanne , Lausanne,","place":["Switzerland"]},{"name":"Department of Neurosurgery, Centre Hospitalier Universitaire Vaudois (CHUV), University of Lausanne , Lausanne,","place":["Switzerland"]},{"name":"Malnati Brain Tumor Institute, Lurie Comprehensive Cancer Center, Northwestern University , Chicago, Illinois,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6171-634X","authenticated-orcid":false,"given":"Wolfgang","family":"Wick","sequence":"additional","affiliation":[{"name":"Neurology Clinic and European Centre for Neurooncology (EZN), University Hospital Heidelberg , Heidelberg,","place":["Germany"]},{"name":"German Consortium of Translational Cancer Research, Clinical Cooperation Unit Neuro-oncology, German Cancer Research Center , Heidelberg,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1748-174X","authenticated-orcid":false,"given":"Michael","family":"Weller","sequence":"additional","affiliation":[{"name":"Department of Neurology, University Hospital and University of Zurich , Zurich,","place":["Switzerland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9949-4722","authenticated-orcid":false,"given":"Martin J B","family":"Taphoorn","sequence":"additional","affiliation":[{"name":"Department of Neurology, Leiden University Medical Center , Leiden,","place":["The Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3648-9616","authenticated-orcid":false,"given":"Johan A F","family":"Koekkoek","sequence":"additional","affiliation":[{"name":"Department of Neurology, Leiden University Medical Center , Leiden,","place":["The Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"EORTC Quality of Life Group and the EORTC Brain Tumor Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,10,1]]},"reference":[{"key":"2026102301370079900_noag231-B1","doi-asserted-by":"publisher","first-page":"1231","DOI":"10.1093\/neuonc\/noab106","article-title":"The 2021 WHO classification of tumors of the central nervous system: a summary","volume":"23","author":"Louis","year":"2021","journal-title":"Neuro Oncol"},{"key":"2026102301370079900_noag231-B2","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1007\/s00066-019-01467-0","article-title":"Pattern of failure in anaplastic glioma patients with an IDH1\/2 mutation","volume":"196","author":"Back","year":"2020","journal-title":"Strahlentherapie Und Onkol Organ Der Dtsch Rontgengesellschaft"},{"key":"2026102301370079900_noag231-B3","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1200\/JCO.2012.43.2674","article-title":"Phase III trial of chemoradiotherapy for anaplastic oligodendroglioma: long-term results of RTOG 9402","volume":"31","author":"Cairncross","year":"2013","journal-title":"J Clin Oncol off J Am Soc Clin Oncol"},{"key":"2026102301370079900_noag231-B4","doi-asserted-by":"publisher","DOI":"10.3390\/ijms23168835","article-title":"Molecular biomarkers in glioblastoma: a systematic review and Meta-Analysis","volume":"23","author":"Sareen","year":"2022","journal-title":"Int J Mol Sci"},{"key":"2026102301370079900_noag231-B5","doi-asserted-by":"publisher","first-page":"4150","DOI":"10.1200\/JCO.2009.21.9832","article-title":"Isocitrate dehydrogenase 1 codon 132 mutation is an important prognostic biomarker in gliomas","volume":"27","author":"Sanson","year":"2009","journal-title":"J Clin Oncol off J Am Soc Clin Oncol"},{"key":"2026102301370079900_noag231-B6","doi-asserted-by":"publisher","first-page":"1564","DOI":"10.1016\/S0140-6736(23)01054-1","article-title":"Primary brain tumours in adults","volume":"402","author":"van den Bent","year":"2023","journal-title":"Lancet"},{"key":"2026102301370079900_noag231-B7","doi-asserted-by":"publisher","first-page":"i38","DOI":"10.1093\/nop\/npae088","article-title":"Symptom management in isocitrate dehydrogenase mutant glioma","volume":"12","author":"Walbert","year":"2025","journal-title":"Neuro-Oncology Pract."},{"key":"2026102301370079900_noag231-B8","doi-asserted-by":"publisher","first-page":"2399","DOI":"10.1093\/neuonc\/noaf108","article-title":"Establishing the content validity of patient-reported outcome measures used in neuro-oncology based on the WHO ICF framework: part of the RANO-PRO initiative","volume":"27","author":"Asogwa","year":"2025","journal-title":"Neuro Oncol"},{"key":"2026102301370079900_noag231-B9","doi-asserted-by":"publisher","first-page":"104147","DOI":"10.1016\/j.critrevonc.2023.104147","article-title":"Prevalence, patterns, and determinants of multimorbidity among childhood and adult cancer survivors: a systematic review","volume":"192","author":"Asogwa","year":"2023","journal-title":"Crit Rev Oncol Hematol"},{"key":"2026102301370079900_noag231-B10","doi-asserted-by":"publisher","first-page":"1442","DOI":"10.1212\/wnl.54.7.1442","article-title":"Long-term outcome of low-grade oligodendroglioma and mixed glioma","volume":"54","author":"Olson","year":"2000","journal-title":"Neurology"},{"key":"2026102301370079900_noag231-B11","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1186\/s12885-021-08102-1","article-title":"Prevalence of multimorbidity in adults with cancer, and associated health service utilization in Ontario, Canada: a population-based retrospective cohort study","volume":"21","author":"Kon\u00e9","year":"2021","journal-title":"BMC Cancer"},{"key":"2026102301370079900_noag231-B12","first-page":"1","author":"Coomans","year":"2022"},{"key":"2026102301370079900_noag231-B13","doi-asserted-by":"publisher","first-page":"1447","DOI":"10.1093\/neuonc\/noz118","article-title":"Symptom clusters in newly diagnosed glioma patients: which symptom clusters are independently associated with functioning and global health status?","volume":"21","author":"Coomans","year":"2019","journal-title":"Neuro Oncol"},{"key":"2026102301370079900_noag231-B14","doi-asserted-by":"publisher","first-page":"1263","DOI":"10.1093\/neuonc\/nou005","article-title":"The combination of IDH1 mutations and MGMT methylation status predicts survival in glioblastoma better than either IDH1 or MGMT alone","volume":"16","author":"Molenaar","year":"2014","journal-title":"Neuro Oncol"},{"key":"2026102301370079900_noag231-B15","doi-asserted-by":"publisher","DOI":"10.3390\/ijms221910373","article-title":"Prognostic and predictive biomarkers in gliomas","volume":"22","author":"\u015aledzi\u0144ska","year":"2021","journal-title":"Int J Mol Sci"},{"key":"2026102301370079900_noag231-B16","doi-asserted-by":"publisher","first-page":"2499","DOI":"10.1056\/NEJMoa1407279","article-title":"Glioma groups based on 1p\/19q, IDH, and TERT promoter mutations in tumors","volume":"372","author":"Eckel-Passow","year":"2015","journal-title":"N Engl J Med"},{"key":"2026102301370079900_noag231-B17","doi-asserted-by":"publisher","first-page":"iii14","DOI":"10.1093\/neuonc\/noaf193.041","article-title":"Os04.2. A final clinical and molecular analysis of the EORTC randomized phase iii intergroup CATNON trial on concurrent and adjuvant temozolomide in anaplastic glioma without 1p\/19q codeletion","volume":"27","author":"Bent","year":"2025","journal-title":"Neuro Oncol"},{"key":"2026102301370079900_noag231-B18","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1093\/neuonc\/noad158","article-title":"Epidemiology and survival of adult-type diffuse glioma in Belgium during the molecular era","volume":"26","author":"Pinson","year":"2024","journal-title":"Neuro Oncol"},{"key":"2026102301370079900_noag231-B19","doi-asserted-by":"publisher","first-page":"e13675","DOI":"10.1097\/MD.0000000000013675","article-title":"IDH mutations but not TERTp mutations are associated with seizures in lower-grade gliomas","volume":"97","author":"Duan","year":"2018","journal-title":"Medicine (Baltimore)"},{"key":"2026102301370079900_noag231-B20","doi-asserted-by":"publisher","first-page":"v1","DOI":"10.1093\/neuonc\/noac202","article-title":"CBTRUS statistical report: primary brain and other central nervous system tumors diagnosed in the United States in 2015-2019","volume":"24","author":"Ostrom","year":"2022","journal-title":"Neuro Oncol."},{"key":"2026102301370079900_noag231-B21","doi-asserted-by":"publisher","first-page":"A453","DOI":"10.1016\/j.jval.2017.08.310","article-title":"Impact of isocitrate dehydrogenase (IDH) status on the performance status and quality of life (QOL) of glioblastoma multiforme (GBM) patients","volume":"20","author":"Waller","year":"2017","journal-title":"Value Heal"},{"key":"2026102301370079900_noag231-B22","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1007\/s11912-020-00978-9","article-title":"Isocitrate dehydrogenase, patient-reported outcomes, and cognitive functioning of glioma patients: a systematic review","volume":"22","author":"Bunevicius","year":"2020","journal-title":"Curr Oncol Rep"},{"key":"2026102301370079900_noag231-B23","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1093\/jnci\/85.5.365","article-title":"The European organization for research and treatment of cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology","volume":"85","author":"Aaronson","year":"1993","journal-title":"J Natl Cancer Inst"},{"key":"2026102301370079900_noag231-B24","doi-asserted-by":"publisher","first-page":"1033","DOI":"10.1016\/j.ejca.2010.01.012","article-title":"An international validation study of the EORTC brain cancer module (EORTC QLQ-BN20) for assessing health-related quality of life and symptoms in brain cancer patients","volume":"46","author":"Taphoorn","year":"2010","journal-title":"Eur J Cancer"},{"key":"2026102301370079900_noag231-B25","volume-title":"The EORTC QLQ-C30 Scoring Manual","author":"Fayers","year":"2001","edition":"3rd"},{"key":"2026102301370079900_noag231-B26","doi-asserted-by":"publisher","first-page":"e97","DOI":"10.1016\/S1470-2045(19)30796-X","article-title":"Glioma patient-reported outcome assessment in clinical care and research: a response assessment in neuro-oncology collaborative report","volume":"21","author":"Armstrong","year":"2020","journal-title":"Lancet Oncol"},{"key":"2026102301370079900_noag231-B27","doi-asserted-by":"publisher","first-page":"1713","DOI":"10.1016\/j.ejca.2012.02.059","article-title":"Evidence-based guidelines for interpreting change scores for the European Organisation for the research and treatment of cancer quality of life questionnaire core 30","volume":"48","author":"Cocks","year":"2012","journal-title":"Eur J Cancer"},{"key":"2026102301370079900_noag231-B28","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1200\/JCO.2010.28.0107","article-title":"Evidence-based guidelines for determination of sample size and interpretation of the European Organisation for the research and treatment of cancer quality of life questionnaire core 30","volume":"29","author":"Cocks","year":"2011","journal-title":"J Clin Oncol off J Am Soc Clin Oncol"},{"key":"2026102301370079900_noag231-B29","doi-asserted-by":"publisher","first-page":"1327","DOI":"10.1093\/neuonc\/noab037","article-title":"Establishing anchor-based minimally important differences for the EORTC QLQ-C30 in glioma patients","volume":"23","author":"Dirven","year":"2021","journal-title":"Neuro Oncol"},{"key":"2026102301370079900_noag231-B30","doi-asserted-by":"publisher","first-page":"2809","DOI":"10.1007\/s11136-025-04029-3","article-title":"Challenges in interpreting individual-level changes in health-related quality of life in patients with glioma using minimally important differences (MIDs) and a 4-point Likert scale","volume":"34","author":"Asogwa","year":"2025","journal-title":"Qual Life Res an Int J Qual Life Asp Treat Care Rehabil"},{"key":"2026102301370079900_noag231-B31","doi-asserted-by":"publisher","first-page":"1656","DOI":"10.1093\/neuonc\/now165","article-title":"Neurocognitive function varies by IDH1 genetic mutation status in patients with malignant glioma prior to surgical resection","volume":"18","author":"Wefel","year":"2016","journal-title":"Neuro Oncol"},{"key":"2026102301370079900_noag231-B32","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1007\/s11136-022-03207-x","article-title":"Health-related quality of life in adults with low-grade gliomas: a systematic review","volume":"32","author":"Rimmer","year":"2023","journal-title":"Qual Life Res an Int J Qual Life Asp Treat Care Rehabil"},{"key":"2026102301370079900_noag231-B33","doi-asserted-by":"publisher","first-page":"1660","DOI":"10.1093\/neuonc\/noac036","article-title":"Tumor-related molecular determinants of neurocognitive deficits in patients with diffuse glioma","volume":"24","author":"van Kessel","year":"2022","journal-title":"Neuro Oncol"},{"key":"2026102301370079900_noag231-B34","doi-asserted-by":"publisher","first-page":"iii121","DOI":"10.1093\/neuonc\/nox036.468","article-title":"P18.04 IDH-1 mutation determines health-related quality of life and cognitive deficit after surgery in high grade glioma","volume":"19","author":"Lee","year":"2017","journal-title":"Neuro Oncol"},{"key":"2026102301370079900_noag231-B35","doi-asserted-by":"publisher","first-page":"212","DOI":"10.3389\/fneur.2019.00212","article-title":"Health related quality of life in adult low and high-grade glioma patients using the national institutes of health patient reported outcomes measurement information system (PROMIS) and neuro-QOL assessments","volume":"10","author":"Gabel","year":"2019","journal-title":"Front Neurol"},{"key":"2026102301370079900_noag231-B36","doi-asserted-by":"publisher","first-page":"1805","DOI":"10.1212\/WNL.0000000000003911","article-title":"Mutant IDH1 and seizures in patients with glioma","volume":"88","author":"Chen","year":"2017","journal-title":"Neurology"},{"key":"2026102301370079900_noag231-B37","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1093\/neuonc\/noab199","article-title":"Importance of the intersection of age and sex to understand variation in incidence and survival for primary malignant gliomas","volume":"24","author":"Wang","year":"2022","journal-title":"Neuro Oncol"},{"key":"2026102301370079900_noag231-B38","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1016\/j.eplepsyres.2014.09.012","article-title":"IDH1\/2 mutation is associated with seizure as an initial symptom in low-grade glioma: a report of 311 Chinese adult glioma patients","volume":"109","author":"Zhong","year":"2015","journal-title":"Epilepsy Res"},{"key":"2026102301370079900_noag231-B39","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1002\/ana.10712","article-title":"Epilepsy in low-grade gliomas: the impact on cognitive function and quality of life","volume":"54","author":"Klein","year":"2003","journal-title":"Ann Neurol"},{"key":"2026102301370079900_noag231-B40","doi-asserted-by":"publisher","first-page":"6256","DOI":"10.1158\/1078-0432.CCR-15-2965","article-title":"Selective detection of the D-enantiomer of 2-Hydroxyglutarate in the CSF of glioma patients with mutated isocitrate dehydrogenase","volume":"22","author":"Kalinina","year":"2016","journal-title":"Clin Cancer Res an off J Am Assoc Cancer Res"},{"key":"2026102301370079900_noag231-B41","doi-asserted-by":"publisher","first-page":"5","DOI":"10.3390\/ijerph18126390","article-title":"Influence of epilepsy on the quality of life of patients with brain tumors","volume":"18","author":"Krajewski","year":"2021","journal-title":"Int J Environ Res Public Health"},{"key":"2026102301370079900_noag231-B42","doi-asserted-by":"publisher","first-page":"100699","DOI":"10.1016\/j.ebr.2024.100699","article-title":"Exercise in patients with epilepsy and neurostimulation devices - physical activity levels, barriers, and beliefs","volume":"27","author":"Mauney","year":"2024","journal-title":"Epilepsy Behav Reports"},{"key":"2026102301370079900_noag231-B43","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1016\/S1474-4422(05)70020-X","article-title":"Epilepsy and social identity: the stigma of a chronic neurological disorder","volume":"4","author":"Jacoby","year":"2005","journal-title":"Lancet Neurol"},{"key":"2026102301370079900_noag231-B44","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1093\/neuonc\/noae186","article-title":"Central nervous system tumors in adolescents and young adults: a society for neuro-oncology consensus review on diagnosis, management, and future directions","volume":"27","author":"Lim-Fat","year":"2025","journal-title":"Neuro Oncol"},{"key":"2026102301370079900_noag231-B45","doi-asserted-by":"publisher","first-page":"2569","DOI":"10.1002\/cncr.23444","article-title":"A gerontologic perspective on cancer and aging","volume":"112","author":"Blank","year":"2008","journal-title":"Cancer"},{"key":"2026102301370079900_noag231-B46","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1080\/13607863.2019.1693972","article-title":"Age differences in cancer-related stress, spontaneous emotion regulation, and emotional distress","volume":"25","author":"Martins-Klein","year":"2021","journal-title":"Aging Ment Health"},{"key":"2026102301370079900_noag231-B47","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1093\/nop\/npae080","article-title":"\u201cAiming at a moving target\u201d-the daily life experiences of adolescents and young adults with a low-grade glioma","volume":"12","author":"Reuvers","year":"2025","journal-title":"Neuro-Oncology Pract"}],"container-title":["Neuro-Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/neuro-oncology\/advance-article-pdf\/doi\/10.1093\/neuonc\/noag231\/71560011\/noag231.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/neuro-oncology\/advance-article-pdf\/doi\/10.1093\/neuonc\/noag231\/71560011\/noag231.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T05:37:08Z","timestamp":1792733828000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/neuro-oncology\/advance-article\/doi\/10.1093\/neuonc\/noag231\/8859115"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,1]]},"references-count":47,"URL":"https:\/\/doi.org\/10.1093\/neuonc\/noag231","relation":{},"ISSN":["1522-8517","1523-5866"],"issn-type":[{"value":"1522-8517","type":"print"},{"value":"1523-5866","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,1]]},"article-number":"noag231"}}